RxDoctor Payments Data

Hoshang Farhad, MD

Cardiovascular Disease · Lincoln, RINPI 1760902530

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (44.6%), education and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Abbott at 37.0% of the total. 2025 is the largest year on record at $999, 3.4 times the $291 reported in 2020.

$2,585in general payments, 2019–2025

Across 32 payments — averaging $80.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$957
  • Biotronik Inc.$327
  • Medtronic$321
  • Astellas Pharma US Inc$297
  • Boston Scientific$186
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$164
  • plus $334 from 5 others

What the payments were for

  • Travel & lodging$59523%
  • Food & beverage$1,15245%
  • Education$83832%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,585 in reported general payments places this provider in the 80th percentile of 86 cardiovascular disease providers in Rhode Island.

See all cardiovascular disease providers in Rhode Island

Medicare billing

Part B allowed, 2024
$40,605
Medicare patients
113
Services billed
302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$35,882
JardianceEmpagliflozin14$21,153
BrilintaTicagrelor21$14,044
Repatha SureclickEvolocumab11$6,326
ClopidogrelClopidogrel Bisulfate64$1,341
Metoprolol Succinate58$1,232
Atorvastatin Calcium58$1,182
Amlodipine Besylate46$214
Hydrochlorothiazide23$147
Spironolactone19$73

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$67$35,88226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 86 cardiovascular disease providers in Rhode Island.

Other cardiovascular disease in Lincoln

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →